< Previous60FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Sunday, 24 April 2022 O0302Model-based TDM of vancomycin: a retrospective comparison with routine TDM-based dosing M. Gijsen* (Leuven, Belgium), H. Gastmans, E. Dreesen, N. Dia, S. Desmet, K. Lagrou, W. Peetermans, Y. Debaveye, I. Spriet O0303Population pharmacokinetics and dosing simulations of cefoxitin administered by continuous IV in critically ill patients P. Chabert* (Lyon, France), J. Provoost, S. Cohen, T. Ferry, J.C. Richard, S. Goutelle O0304Pharmacokinetics and PK/PD of temocillin in non-ICU urinary tract infection patients with various stages of renal insufficiency G. Wijnant* (Brussels, Belgium), P. Ngougni Pokem, M. Coessens, E. Cottone, L. Goeman, S. Vervaeke, F. Van Bambeke O0305Pharmacokinetics and safety of colistin in older adults with extensively drug-resistant Gram- negative bacterial infections S. Luque* (Barcelona, Spain), L. Sorli, I. Arnau, R. Güerri, N. Campillo, J. Gomez-Junyent, I. Pelegrin, S. Gómez-Zorrilla, I. Lopez, M. Arenas, M. Montero, S. Grau, J.P. Horcajada O0306Population pharmacokinetics and probability of target attainment analyses of ceftolozane/ tazobactam in paediatric participants J. Chittenden* (Kenilworth, United States), N. Noormohamed, S. Basu, W. Gao, M.G. Johnson, C.J. Bruno, H.P. Feng O0307Therapeutic drug monitoring of orally administered letermovir prophylaxis in allogeneic haematopoietic cell transplant recipients L. Royston* (Geneva, Switzerland), S. Masouridi- Levrat, Y. Chalandon, C. Pressacco-Brossier, Y. Abi Aad, D. Tonoli, A. Karmime, M. Jayo, V. Gotta, M. Pfister, C. Van Delden, P. Lescuyer, D. Neofytos O0308Plasma pharmacokinetics and intrapulmonary penetration of tebipenem in healthy subjects K. Rodvold* (Chicago, United States), M. Gotfried, V. Gupta, A. Ek, Y. Lei, P. Srivastava, A. Talley, J. Bruss O0309Amoxicillin crystalluria in patients receiving high doses of intravenous amoxicillin: incidence, associated factors and impact on renal function, the CRISTAMOX study M. Hentzien* (Reims, France), S. Demotier, A. Limelette, A. Charmillon, E. Baux, X. Parent, S. Mestrallet, S. Pavel, A. Servettaz, M. Dramé, A. Muggeo, A. Wynckel, C. Gozalo, M. Abou Taam, A. Fillion, R. Jaussaud, T. Trenque, L. Piroth, F. Bani-Sadr OS076 08:30 - 10:30 Hall K 2-Hour Oral Session Endocarditis, mice and men ChairsXavier Duval (Paris, France) José M. Miro (Barcelona, Spain) O0310Culture negative endocarditis and the value of a definite diagnosis: results from a tertiary care centre of northern Italy T.C. Pieri* (Pavia, Italy), E. Seminari, P. Cambieri, S. Roda, M. Colaneri, I. Gallazzi, E. Asperges, E. Bono, L.N. Marvulli, R. Lissandrin, R. Bruno O0311Bone marrow and spleen hypermetabolism as indirect signs of infection in an experimental endocarditis animal model C. García De La Mària* (Barcelona, Spain), A. Perissinotti, M. Collantes, J. Llopis, M. Ecay, M.J. García-Velloso, J. García González, M.A. Cañas, M. Hernández-Meneses, A. Moreno, I. Peñuelas, D. Fuster, J.M. Miró O0312Efficacy of the activity of daptomycin with ceftaroline against isolated Staphylococcus epidermidis causing infectious endocarditis C. García De La Mària* (Barcelona, Spain), M. Cañas, M. Hernández Meneses, J. García González, A. Dahl, C. Falces, E. Quintana, J. Llopis, J. Ambrosioni, F. Marco, B. Vidal, A. Perissinotti, J.M. Tolosana, E. Sandoval, A. Moreno, J.M. Miró O0313Epidemiology, clinical characteristics and outcome of 187 patients with infective endocarditis from 2009 to 2021 at two university hospitals, in Rio de Janeiro, Brazil P. Damasco* (Rio de Janeiro, Brazil), L. Sousa, V. Solórzano, N. Rodrigues, A. Siebra, H. Coutinho, R. Leão, E. Lemos, C. Fortes O0314Outpatient parenteral antimicrobial therapy (OPAT) for infective endocarditis: convenient and feasible L.E. Lopez-Cortés* (Seville, Spain), R. Luque- Márquez, L. Hidalgo-Herrera, M.D. Navarro-Amuedo, J. Praena-Segovia, M.V. Gil-Navarro, A. Alarcón- Gonzalez O0315Influence of the antithrombotic therapy in the prognosis of infective endocarditis J.T. Solera* (Toronto, Canada), L. Domínguez Pérez, P. Muñoz, M. Martínez-Sellés, A. De Alarcón, C. Rico, L. García, M.Á. Goenaga, J. Goikoetxea, R. Rodríguez, J. De La Torre, D. Escribano, L. Boix, L. Castelo, F. López Medrano O0316Infective endocarditis and cardiovascular outcomes after transcatheter and surgical aortic valve replacement: a population-based cohort study M. Purtak* (Aarau, Switzerland), A. Kutz*, A. Conen* O0317Risk factors for Gram-negative infection of cardiovascular implantable electronic devices: retrospective multi-centre study, CarDINe study R. Pascale* (Bologna, Italy), A.T. Aslan, A. Maccaro, G. Massaro, A. Toschi, D. Fabbricatore, T. De Potter, M. Ripa, P. Scarpellini, A. Karruli, E. Durante-Mangoni, K. Akinosoglou, G. Leventopulos, M. Papadimitriou-Olivgeris, G. Domenichini, E.E. Özcan, O.E. Turan, M. Yilmaz, M. Sahin, M.C. Isik, B. Kayaaslan, Y.A. Bilir, S. Iacopino, F. Placentino, M. Akova, I. Diemberger, P. Viale, M. GiannellaScientific Programme 61FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Sunday, 24 April 2022 O0318Systemic embolism in infective endocarditis J. Constán* (Granada, Spain), C. López-Robles, M.C. García, C. Fernández-Roldán, R. Javier O0319Risk of infective endocarditis associated with transcatheter aortic valve implantation versus surgical aortic valve replacement: a propensity score-based analysis on a prospective cohort J. Calderon Parra* (Majadahonda, Spain), J.E. De Villarreal-Soto, J.F. Oteo-Domínguez, C. Arellano-Serrano, M. Mateos-Seirul, D. Martínez- López, L. Dorado, E.C. Ríos-Rosados, A. Ramos- Martínez, A. Forteza-Gil OS07708:30 - 09:30 Hall D 1-Hour Case Session Challenges associated with Capnocytophaga infections ChairEls Broens (Utrecht, Netherlands) O0320Same pathogen, different outcome in immunocompetent patients: Capnocytophaga canimorsus; report of two cases A. Perez-Ugarte* (Barcelona, Spain), S. Levy- Blitchtein, P. Salmeron, M. Belsol, P.S. Corona, D. Rodríguez-Pardo, N. Fernández-Hidalgo, C. Amat, M. Lung O0321Capnocytophaga canimorsusmeningitis: a nationwide population-based case series L. Duerlund* (Aalborg, Denmark), H. Nielsen, J. Bodilsen O0322Capnocytophaga canimorsus: not always the dog is the man´s best friend D. Fernández Vecilla* (Bilbao, Spain), I. Angulo López, F.E. Calvo Muro, C. Aspichueta Vivanco, F. Renzi, M.E. Pereda Martínez, J. Roselló Soria, J.L. Díaz De Tuesta Del Arco O0323Capnocytophaga canimorsus multifocal mycotic aneurysms in an immunocompetent adult C. Sun* (Adelaide, Australia), A. Fitzpatrick, E. Tucker O0324Lethal Waterhouse-Friderichsen syndrome caused by Capnocytophaga canimorsus in an asplenic patient F. Schuler* (Münster, Germany), J.S. Padberg, C. Hullermann, P. Kümpers, J. Lepper, M. Schulte, A. Uekötter, F. Schaumburg, C.B. Kahl VW078 08:30 - 09:30 Arena 2 Virtual Walk Through Multiple drug-resistant bacteria and COVID-19: a double whammy ModeratorGian Maria Rossolini (Florence, Italy) ReviewerSarah Tschudin Sutter (Basel, Switzerland) VW079 09:30 - 10:30 Arena 1 Virtual Walk Through Staphylococcus aureus, a long way to the top ModeratorBarbara C. Kahl (Münster, Germany) ReviewerSerap Simsek Yavuz (Erenkoy, Istanbul, Turkey) PH KN08011:00 - 12:00Hall A Keynote lecture Dealing with the complexity of pandemics: the future is now Chairs Marion Koopmans (Rotterdam, Netherlands) Jacob Moran-Gilad (Be'er Sheva, Israel) K032511:00 Chikwe Ihekweazu (Berlin, Germany) Dr Chikwe Ihekweazu is the Assistant Director General at WHO for Surveillance and Health Emergency Intelligence and leads the WHO Hub for Pandemic and Epidemic Intelligence, based in Berlin, Germany. Previously, Dr Ihekweazu was the firstDirectorGeneraloftheNigeriaCentreforDiseaseControl (NCDC), which he led July 2016 - October 2021, building it from a small unit to a leading public health agency in Africa. He acted as Interim Director of the West Africa Regional Centre for Surveillance and Disease Control through 2017. He trained as an infectious disease epidemiologist and has over 25 years’ experience working in senior public health and leadership positions in national public health institutes including NCDC, South African National Institute for Communicable Diseases, the UK's Health Protection Agency, and Germany’s Robert Koch Institute. Dr Ihekweazu has led several short-term engagements for WHO, mainly building surveillance systems and responding to major infectious disease outbreaks. He waspartofthefirstWHOCOVID-19internationalmissionto China. Dr Ihekweazu is a graduate of the College of Medicine, University of Nigeria and has a Master’s in Public Health from the Heinrich-Heine University, Dusseldorf, Germany. In 2003, he was awarded a Fellowship for the European Programme for Intervention Epidemiology Training and subsequentlycompletedhisPublicHealthspecialisation in the UK. He has over one hundred publications in medical peer review journals, mostly focused on the epidemiology of infectious diseases. Dr Ihekweazu is on the board of severalNGOs;hewasalsoaTEDFellowandco-founded and delivered the TEDxEuston event from 2009 to 2019. Fireplace Session24 April, 12:30 - 13:3062FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Sunday, 24 April 2022 ID SY081 11:00 - 12:00 Hall C Symposium Hepatitis E: an update ChairsGülsen Özkaya Sahin (Lund, Sweden) Zeinab Said (Cairo, Egypt) S032611:00Transfusion-associated fulminant HEV infection Heli Harvala (London, United Kingdom) S032711:30Prospects for an HEV vaccine Susanne Gjeruldsen Dudman (Oslo, Norway) Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH) ID SY082 11:00 - 12:00 Hall E Symposium Year in Infectious Diseases ChairsGraeme Ayton Meintjes (Cape Town, South Africa) Joanne M Langley (Halifax, Canada) S032811:00Synne Jenum (Oslo, Norway) S032911:30Elena Carrara (Verona, Italy) CM SY083 11:00 - 12:00 Hall F Symposium Fighting biofilm with non-traditional antibacterials ChairsRan Nir-Paz (Jerusalem, Israel) Zuzanna Drulis-Kawa (Wroclaw, Poland) S033011:00Antisense therapy against biofilms Nuno Azevedo (Porto, Portugal) S033111:30Phage-inspired leads for antibiotics Rob Lavigne (Leuven, Belgium) Co-organised with: ESCMID Study Group for Non- traditional Antibacterial Therapy (ESGNTA), ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS) ID SY084 11:00 - 12:00 Hall I Symposium Combination therapies: from models to patients ChairsAlexia Chauzy (Poitiers, France) Yunsong Yu (Hangzhou, China) S033211:00Favourable combination therapies evidence from pre-clinical studies Thomas Tängdén (Uppsala, Sweden) S033311:30Combination therapies in clinical trials: what is the evidence? Dafna Yahav (Petah-Tikva, Israel) CM SY085 11:00 - 12:00 Hall N Symposium Updates on antimicrobial susceptibility testing of mycobacteria ChairsFlorian Maurer (Borstel, Germany) Thomas Schön (Kalmar, Sweden) S033411:00Updates and open questions on the recently revised WHO critical concentrations for antimicrobial susceptibility testing of Mycobacterium tuberculosis complex Claudio Köser (Cambridge, United Kingdom) S033511:30The EUCAST approach for drug susceptibility testing of mycobacteria: past, present, future Emmanuelle Cambau (Paris, France) Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), EUCAST Subcommittee on Antimycobacterial Susceptibility Testing (EUCAST-AMST) OS086 11:00 - 12:00 Hall B 1-Hour Oral Session Rapid detection of emerging SARS-CoV-2 variants ChairsSimona Ruta (Bucharest, Romania) Anja Šterbenc (Ljubljana, Slovenia) O0336Comparative analysis of five multiplex real-time RT-qPCR assays in the screening of SARS-CoV-2 variants I. Giberti* (Genoa, Italy), V. De Pace, B. Bruzzone, A. Orsi, V. Ricucci, A. Domnich, G. Guarona, N. Randazzo, F. Stefanelli, E. Battolla, P.A. Dusi, F. Lillo, G. Icardi O0337Early detection of SARS-CoV-2 variants through the application of SNP based genotyping in anational surveillance programme S. Choudhry* (London, United Kingdom), M. Edmunds, W. Sopwith, H. Vansteenhouse, M. Wigglesworth, J.A. O’hare, J. Turner, M.A. Amphlett, M.L. Smith, J. Cogdale, J. Ellis, A. Lackenby, K. Mcclelland, T. Rowland, K. Rajput, P. Jacobs, J. Feenstra, A.F. Dominiczak, M. Zambon O0338Clinical evaluation of commercial SARS-CoV-2 variant assays A. De Salazar* (Granada, Spain), A. Fuentes-López, L. Viñuela, N. Chueca, F. García O0339Identification of SARS-CoV-2 lineage and mutations with a rapid SARS-CoV-2 genotyping assay C. Lee* (Singapore, Singapore), I. Ng, B. Han, F. Kadir, A. Aizin, H. Suhardi, M. Aye, A.W. Kyaw, P. Ariyaratne, W.K. Lye, R. Luo O0340A metagenomics workflow for SARS-CoV-2 identification, co-pathogen detection, and overall metagenome diversity in clinical isolates D. Castañeda-Mogollón* (Calgary, Canada), C. Kamaliddin, L. Oberding, Y. Liu, M.A.N. Mohon, F. Rehan, F. Khan, D. PillaiScientific Programme 63FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 Sunday, 24 April 2022 OS087 11:00 - 12:00 Hall G 1-Hour Oral Session UTI: from mild to complicated, from diagnosis to treatment ChairsMarco Falcone (Pisa, Italy) Cees Van Nieuwkoop (The Hague, Netherlands) O0341Use of urinary dip sticks in hospital care: a population-based cohort study W. Rannva* (Aalborg, Denmark), R. Winther, L.H. Kristensen, H. Nielsen, J. Bodilsen O0342Effectiveness and safety of intravenous fosfomycin in complicated urinary tract infection in real-life conditions: preliminary results from a matched-cohort study (FOSFO-MIC) E. Moreno-Mellado* (Seville, Spain), E. León Jiménez, C. Garrigós, S. De La Rosa-Riestra, J. Liró Armenteros, J.L. Rodríguez-Ochoa, E.L.I.S.A. Asensio Gallego, M. Akova, C.D. Zeynep, A. Tarik Aslan, D. Vinuesa, E. Moral Escudero, N. Chacón Mora, Á. Cano, Á. Pascual Hernández, J. Rodríguez- Baño, F. Docobo Pérez, B. Gutiérrez-Gutiérrez O0343Effectiveness at day 5 of antimicrobial treatment for uncomplicated febrile urinary tract infection in children between 3 months to 18 years old, pilot study PEDIU5 A. Zeggay* (Besançon, France), A. Ladaurade, A. Potron, A.L. Parmentier, G. Thiriez, R. Anxionnat O0344Bacterial genome-wide association study identifies papGII to be associated with invasive uropathogenic E. coliinfections A. Cuénod* (Basel, Switzerland), J. Agnetti, H. Seth-Smith, T. Roloff, S. Tschudin-Sutter, S. Bassetti, N.R. Thomson, A. Egli O0345The comparative efficacy of various oral therapeutics to treat mild urinary tract infections, which are managed in the community, caused by extended-spectrum beta-lactamase producing Enterobacterales (ESBL) D. Marchaim* (Be’er Ya’akov, Israel), E. Levy, S. Zilberman-Itskovich, I. Levi, M. Iflah, K. Amity, R. Finkenberg OS088 11:00 - 12:00 Hall H 1-Hour Oral Session Resistance markers in sexually transmitted bacteria ChairsBenjamin Bluemel (Solna, Sweden) Angelika Stary (Vienna, Austria) O0346Emergence of extended-spectrum beta- lactamases producing Shigella sonnei among men who have sex with men in Barcelona A. Moreno-Mingorance* (Barcelona, Spain), V. Rodriguez-Garrido, L. Goterris, Y. Hoyos-Mallecot, M.J. Barberà, M. Alberny, E. Sulleiro, A. Mir-Cros, J. Roca-Grande, T. Cornejo-Sánchez, B. Viñado, T. Pumarola, M.N. Larrosa, J.J. González-López O0347N. gonorrhoeae azithromycin resistance: the push and pull of evolutionary forces P. Campbell* (Oslo, Norway), L.M. Brendefur Corwin, J.V. Bjørnholt, A.O. Olsen, T.M. Leegaard O0348Fluoroquinolone resistance-associated mutations in Mycoplasma genitalium among men with urethritis and other clients of two Sexual Health Centres in the Netherlands J. Braam* (Amsterdam, Netherlands), H.C.A. Zondag, S.M. Bruisten, H.J.C. De Vries, C.E. Vergunst, M.F. Schim Van Der Loeff, A.P. Van Dam O0349The Neisseria gonorrhoeae accessory genome and its association with the core genome and antimicrobial resistance J. De Korne-Elenbaas* (Amsterdam, Netherlands), S.M. Bruisten, A.P. Van Dam, M.C.J. Maiden, O.B. Harrison O0350Distinct Mycoplasma genitalium transmission networks among women and PrEP users in France J. Guiraud* (Bordeaux, France), M. Helary, C. Le Roy, S. Pereyre, C. Bébéar OS089 11:00 - 12:00 Hall Q 1-Hour Oral Session Pathophysiology and prognosis in COVID-19 infection ChairsChrysanthi Skevaki (Marburg, Germany) Snjezana Zidovec Lepej (Zagreb, Croatia) O0351Biological and clinical significance of natural circulating and airway neutralising antibodies to IFN-I in COVID-19 patients F. Frasca* (Rome, Italy), M. Scordio, L. Sorrentino, M. Fracella, G. Oliveto, A. Viscido, C. Bitossi, A. D’auria, G. Bugani, L. Santinelli, A. Pierangeli, L. Celani, G. Ceccarelli, C.M. Mastroianni, G. D’ettorre, G. Antonelli, C. Scagnolari O0352High levels of IL-6 and SARS-CoV-2 viral load and low expression of CCL5 in the upper respiratory tract are associated with severe COVID-19 F. Pérez-García* (Majadahonda, Spain), M. Martín- Vicente, R.L. Rojas-García, L. Castilla-García, M.J. Muñoz-Gómez, I. Hervás Fernández, V. González Ventosa, E.J. Vidal-Alcántara, J. Cuadros-González, M.Á. Jiménez-Sousa, A. Fernández-Rodríguez, J.F. Bermejo-Martín, S. Resino, I. Martínez O0353Evaluation of neurofilament light chain in cerebrospinal fluid and plasma samples of COVID-19 patients with neurological symptoms M.A. Zingaropoli* (Rome, Italy), M. Iannetta, L. Piermatteo, P. Pasculli, L. Mazzuti, R. Scutari, L. Onori, L. Campogiani, G. Ferraguti, G. Antonelli, M. Andreoni, C.M. Mastroianni, O. Turriziani, F. Ceccherini-Silberstein, L. Sarmati, M.R. Ciardi O0354COVID-19 alters oral microbiome in closed community on a cruise ship K. Ota* (Nagasaki, Japan), D. Sasaki, F. Mitsumoto-Kaseida, K. Sakamoto, K. Kosai, H. Hasegawa, K. Yamamoto, K. Izumikawa, H. Mukae, K. Yanagihara64FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 O0355Association of vitamin D with severity and outcome of COVID-19: clinical and experimental evidence E. Giamarellos-Bourboulis* (Athens, Greece), G. Renieris, G. Kassianidis, G. Damoraki, D.I. Droggiti, T. Gkavogianni, P. Koufargyris, K. Katrini OS090 11:00 - 12:00 Hall D 1-Hour Case Session Unusual fungal infections from around the globe ChairJoseph Meletiadis (Athens, Greece) O0356Adjunctive imiquimod for chromoblastomycosis: lending innate immunity a helping hand C. Logan* (London, United Kingdom), S. Krishna, N. Fox, M. Singh, K. Gordon, D. Macallan, T. Bicanic O0357Subcutaneous mycosesdue toEmergomyces pasteurianus: the first case report in Thailand L. Srikham* (Bangkok, Thailand), A. Chindamporn, R. Plongla O0358Invasive cerebral aspergillosis in non- neutropenic patients: a case series from western India D. Kumar* (Jodhpur, India), S. Samantaray, G.K. Bohra, V. Jain, S. Tiwari, D.S. Meena, N. Midha O0359Subcutaneous hyalohyphomycosis caused by Fusarium solani successfully treated with surgical removal in immunocompetent host M. Harnphadungkit* (Bangkok, Thailand), P. Phuensan O0360Mycobiome analysis reveals high fungal richness in lungs of acute respiratory distress syndrome after septic tank incident J. Kehrmann* (Essen, Germany), H.L. Verhasselt, M. Kudla, F. Herbstreit, S. Weidener, F. Reckinger, R. Scholtysik, J. Buer OF091 11:00 - 12:00 Hall K 1-Hour Mini-oral Flash Session New insights into pathogens virulence: human and microbial factors ChairsSusanne Haeussler (Braunschweig, Germany) Kimberly Kline (Singapore, Singapore) O0361Impact of peptidoglycan amidation on cell surface properties and biofilm formation in Staphylococcus aureus G. Cavaco* (Caparica, Portugal), B. Gonçalves, I. Grilo, H. De Lencastre, M. Miragaia, R. Sobral O0362CD6 deficiency impacts early immune response to bacterial sepsis C. Català* (Barcelona, Spain), M. Velasco-De Andrés, A. Leyton-Pereira, S. Casadó-Llombart, M. Martinez-Florensa, M. Saéz-Moya, R. Gutiérrez- Cózar, J. Garcia-Luna, F. Aranda, M. Consugra- Fernández, G. Mourglia-Ettlin, P. Engel, F. Lozano O0363Identification of novel small non-coding RNAs involved in biofilm and antibiotic resistance V. Pobre* (Oeiras, Portugal), B. Carvalho, C. Arraiano O0364Peptidoglycan recyclingenzymes AmpD and AnmK contribute to biofilm formation and twitching motility inA. baumannii A. Tajuelo* (Majadahonda, Spain), M. Lopez-Siles, M.C. Terrón, M. Sachse, D. Luque, M.J. Mcconnell O0365Biocides contribute to antibiotic resistance spread by increase functional eDNA release from biofilms O. Moshynets* (Kiev, Ukraine), T. Baranovskyi, O. Iungin, N. Kysil, L. Metelytsia, I. Pokholenko, V. Potochilova, G. Potters, K. Rudnieva, S. Rymar, I. Semenyuta, A. Spiers, O. Tarasyuk, S. Rogalsky O0366The acquisition of additional feedback loops optimises and speeds up the response of quorum sensing M. Fondi* (Florence, Italy), F. Di Patti, E. Perrin O0367Differential biofilm formation capacity and evolution in Candida glabrata clinical isolates: a genomics view I. Costa* (Lisbon, Portugal), P. Pais, M. Zolotareva, M. Cavalheiro, M. Galocha, R. Viana, M. Cacho Teixeira O0368Glycopeptidolipid(GPL) defects donot affect survival of rough Mycobacterium abscessus isolates on fomites and in chlorhexidine, as compared to their isogenic smooth counterparts M. Meir* (Haifa, Israel), D. Barkan O0369Catecholamine neurotransmitters are able to be used by Pseudomonas aeruginosa cells to access iron, a key nutrient I. Schalk* (Illkirch, France), Q. Perraud, S. Fritsch OF092 11:00 - 12:00 Hall L 1-Hour Mini-oral Flash Session Pathogenesis of fungal infections: the host and pathogen point of view ChairsElisa Borghi (Milan, Italy) Mihai Mares (Iasi, Romania) O0370Caenorhabditis elegans as a model for the study of dermatophyte infection and evaluation of 2-hydroxychalcone mediated by photodynamic therapy toxicity M.J.S. Mendes-Giannini* (Araraquara, Brazil), N.M.B. Bila, C.O.V. Vaso, L.R. De Assis, L.O. Regasini, C.R. Fontana, A.F.A. Ana Marisa, C.O. Caroline Barcelos O0371Myeloid immunity-driven gene expression profiling in bronchoalveolar lavage fluid of influenza- and COVID-19-associated pulmonary aspergillosis S. Feys* (Leuven, Belgium), C. Jacobs, L. Vanderbeke, L. Seldeslachts, M.R. Starick, K. Thevissen, Y. Debaveye, G. Hermans, P. Meersseman, K. Lagrou, A. Carvalho, J. Van Weyenbergh, J. Wauters Sunday, 24 April 2022Scientific Programme 65FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 O0372Candida albicans expresses an integrin-like adhesin that binds to the endothelium and triggers vascular disruption through a VE- cadherin signalling cascade D. Nader* (Dublin, Ireland), G. Curley, S. Kerrigan O0373Intestinal mycobiome compositional shifts and impaired Th17 signalling are associated with NAFLD severity N. Thielemann* (Würzburg, Germany), S. Leal Siliceo, R. Martin, M. Herz, M. Rau, H. Hermanns, A. Geier, G. Panagiotou, O. Kurzai O0374Microbial factors involved in the pathogenesis of vulvovaginal candidiasis: from carrier state to recurrent disease D. Shasha* (Tel Aviv, Israel), M. Elbaz, N. Mizrahi, A. Novikov, A. Lev-Sagie, R. Ben-Ami O0375Overcome double trouble: baloxavir marboxil suppresses influenza thereby mitigating secondary invasive pulmonary aspergillosis L. Seldeslachts* (Leuven, Belgium), C. Jacobs, B. Tielemans, E. Vanhoffelen, L. Van Der Sloten, S. Humblet-Baron, L. Naesens, K. Lagrou, E. Verbeken, J. Wauters, G. Vande Velde O0376Blockade of the PD-1/PD-L1 immune checkpoint pathway enhances host defense against Mucorales and improves outcomes in a murine model of invasive pulmonary mucormycosis S. Wurster* (Houston, United States), N.D. Albert, U. Bharadwaj, M.M. Kasembeli, D.P. Kontoyiannis O0377Unraveling host-pathogen interactions upon Candida auris infection: fungal behaviour and immune response in Galleria mellonella V. Garcia-Bustos* (Valencia, Spain), J. Peman, A.C. Ruiz-Gaitan, M.D. Cabanero-Navalon, A. Cabanilles-Boronat, L. Marcilla-Barreda, M. Fernandez-Calduch, I.A. Sigona-Giangreco, M. Salavert, M.Á. Tormo, A. Ruiz-Sauri O0378Gastrointestinal tract Candida spp. colonisation is mostly monoclonal: results derived from an intra-patient pilot study A. Mesquida* (Madrid, Spain), T. Vicente, P. Muñoz, J. Guinea, P. Escribano OF093 11:00 - 12:00 Hall M 1-Hour Mini-oral Flash Session COVID-19 vaccine immunogenicity and effectiveness in the immune compromised host ChairsMurat Akova (Ankara, Turkey) Marco Safadi (São Paulo, Brazil) O0379SARS-CoV-2 vaccine responses in patients with conditions leading to diminished immune capacity: the OCTAVE and OCTAVE-DUO trials T. De Silva* (Sheffield, United Kingdom) O0380Humoral and T cell specific immune responses to SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis using different disease- modifying therapies A. Aiello* (Rome, Italy), C. Tortorella, C. Gasperini, C. Agrati, C. Castilletti, S. Ruggieri, S. Meschi, G. Matusali, F. Colavita, C. Farroni, G. Cuzzi, E. Cimini, E. Tartaglia, V. Vanini, L. Prosperini, S. Haggiag, S. Galgani, M.E. Quartuccio, A. Salmi, F. Repele, A.M.G. Altera, F. Cristofanelli, A. D’abramo, N. Bevilacqua, A. Corpolongo, V. Puro, F. Vaia, M.R. Capobianchi, G. Ippolito, E. Nicastri, D. Goletti O0381Evaluation of the B and T cell response in patients with rheumatoid arthritis at one and six months following SARS-CoV-2 mRNA vaccination C. Farroni* (Rome, Italy), A. Picchianti-Diamanti, A. Aiello, B. Laganà, C. Agrati, C. Castilletti, S. Meschi, D. Lapa, S. Najafi Fard, G. Cuzzi, E. Cimini, G. Grassi, V. Vanini, A. Salmi, F. Repele, A.M.G. Altera, V. Puro, E. Nicastri, D. Goletti O0382Torquetenovirus viral load is predictive of SARS-CoV-2 vaccine response in lung transplant recipients F. Gallais* (Strasbourg, France), M. Solis, B. Renaud-Picard, A. Velay, M.J. Wendling, S. Caillard, R. Kessler, S. Fafi-Kremer O0383SARS-CoV-2 serological data and cellular response of patients withHIV during pre- and post-vaccination period in Tel Aviv Sourasky Medical Center T. Halperin* (Tel Aviv, Israel), L. Tau, D. Turner, A. Adler, R. Marom, S. Ahsanov, I. Levi, N. Matus, G. Gerber, S. Lev, T. Freund, D. Hagin O0384Analysis of post-vaccinal neutralising response against wild-type SARS-CoV-2 and Delta variant in haemodialysis patients and kidney recipients S. Alain* (Limoges, France), F. Lamarche, S. Hantz, C. Danthu, J.P. Rerolle, F. Toure O0385Comprehensive profiling of immune response to COVID-19 vaccination in patients with haematological malignancy B. Teh* (Melbourne, Australia), O. Nguyen, C. Lim, S. Tennakoon, N. Saunders, L. Rowntree, L. Allen, B. Chua, L. Kedzierski, L. Chee, M. Anderson, J. Seymour, M. Slavin, C. Tam, K. Kedzierska O0386Poor humoral immunogenicity to SARS-CoV-2 vaccination in people living with HIV (PLWH) with low CD4 count A. Antinori* (Rome, Italy), A. Cozzi-Lepri, A. Vergori, A. Tavelli, L. Marconi, S. Cicalini, A.M. Azzini, A. Sartor, A. Rodano’, S. Meschi, C. Agrati, F.M. Fusco, E. Righi, F. Abrizzani, G. Marchetti, E. Girardi, P. Viale, M. Giannella, E. Tacconelli, A. D’arminio Monforte Sunday, 24 April 202266FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 O0387Response to SARS-CoV-2 vaccination in patients with antibody deficiency disorders C. Bracke-Manzanares* (Badalona, Spain), E. Ainsua-Enrich, N. Pedreño, M. Rodríguez De La Concepción, C. Ávila-Nieto, E. Pradenas, S. Marfil, R. Toledo, M. Font, C. Miranda, S. González, J. G. Prado, B. Mothe, C. Brander, N. Izquierdo- Useros, J. Vergara-Alert, J. Segalés, M. Massanella, R.M. Benítez, A. Romero, D. Molina-Morant, J. Blanco, B. Clotet, L. Mateu, J. Carrillo, M.L. Pedro- Botet OF09411:00 - 12:00 Hall O 1-Hour Mini-oral Flash Session New faces in the camp of AMR pathogens ChairsTBA Cecile Bebear (Bordeaux, France) O0387AAzithromycin resistanceinEscherichia coliandSalmonellafrom food-producing animals and meat in Europe M. Ivanova* (Kongens Lyngby, Denmark), A. Ovsepian, P. Leekitcharoenphon, A.M. Seyfarth, H. Mordhorst, S. Koeberl-Jelovcan, M. Milanov, G. Kompes, M. Liapi, T. Č erný, C. Thougaard Vester, A. Perrin-Guyomard, J. Hammerl, M. Grobbel, E. Valkanou, S. Jánosi, R. Slowey, P. Alba, V. Carfora, J. Avsejenko, A. Ceslova, A. Pereckiene, S. Sceponaviciene, D. Claude, R. Zerafa, K. Veldman, C. Boland, C. Garcia-Graells, P. Butaye, P. Wattiau, M. Zaj ą c, A. Ana, L. Clemente, M. Vaduva Angela, L.M. Romascu, N.M. Milita, A. Mojžišová, I. Zdovc, M.J. Zamora Escribano, C. De Frutos Escobar, K. Pedersen, G. Overesch, C. Teale, A.M.V. Brown, G.H. Loneragan, B. Guerra, P.A. Beloeil, R.S. Hendriksen, J.S. Kjeldgaard, V. Bortolaia O0388Legionella pneumophila antibiotic resistance: from myth to reality S. Jarraud* (Lyon, France), C. Ginevra, L. Beraud, H. Bentayeb, C. Allam, J. Chastang, M. Ibranosyan, V. Decroix, G. Descours O0389Antibiotic resistance prevalence in Helicobacter pylori in gastric biopsies A. Bellés-Bellés* (Lleida, Spain), S. Mormeneo Bayo, D. Bayas Pastor, R. Monclus Millanes, S. Chordi Barrufet, M.L. Cruellas Tremps, A. Jover Saenz, M. Planella De Rubinat, M. Garcia Gonzalez O0390Antimicrobial susceptibility testing: the intriguing scenario in anerobes clinical isolates M. Casarotto* (Verona, Italy), M. Tartaglia, D. Gibellini, A. Mazzariol O0391National survey of antimicrobial resistance amongst clinical Bacteroides and Prevotella isolates in The Netherlands K. Boiten* (Groningen, Netherlands), D. Notermans, R. Rentenaar, J. Van Prehn, L. Bode, I. Maat, W. Van Der Zwet, N. Arents, T. Siebers, S. De Greeff, A. Hendrickx, E. Kuijper, L. Veloo O0392Genome analysis of macrolide-resistant Haemophilus influenzaeandHaemophilus parainfluenzaestrains isolated at Bellvitge University Hospital I. Cadenas Jiménez* (Barcelona, Spain), A. Carrera Salinas, A. González Díaz, L. Saiz Escobedo, D.A. Vázquez Sánchez, S. Calvo Silveria, D. Berbel, F. Tubau, C. Ardanuy, S. Martí O0393Alarming increase in antimicrobial resistance in Helicobacter pylori in the Netherlands, 2010- 2019 S. Woudt* (Bilthoven, Netherlands), R. Veenendaal, A. Schoffelen, E. Kuijper O0394Antibiotic resistance in Haemophilus influenzae isolates obtained from patients at outpatient departments in Germany, 2019/2020 H. Claus* (Würzburg, Germany), T.T. Lâm, E. Wohlfarth, U. Vogel, M. Kresken O0395Population structure of carbapenemase- producing Morganella spp. R. Bonnin* (Le Kremlin-Bicetre, France), E. Creton, A. Perrin, D. Girlich, A.B. Jousset, C. Emeraud, K. Hopkins, P. Bogaerts, N. Pfennigwerth, M. Gniadkowski, A. Hendrickx, K. Van Der Zwaluw, P. Apfalter, R. Hartl, V. Heringova, J. Hrabak, G. Larrouy-Maumus, E. Rocha, T. Naas, L. Dortet FO095 12:15 - 13:15 Arena 1 Open Forum Is Twitter the new ID textbook? ChairJose Ramon Pano-Pardo (Zaragoza, Spain) F0396RIP my mentions: science by social media in the age of disinformation Angela Rasmussen (Saskatoon, Canada) F0397Is social media worth my time? Carlos Del Rio (Atlanta, United States) F0398#IDTwitter: infectious diseases medicine in the age of social media Stone Neil (London, United Kingdom) F0399Bugs, drugs, and social media: Twitter as a tool for advancing the field of infectious diseases Timothy Gauthier (Miami, United States) FO095A 12:15 - 13:15 Arena 2 Open Forum When science gets politicised; experiences from the COVID-19 pandemic ChairInes Steffens (Solna, Sweden) F0399AIn the eye of the public: politicised science, the epidemiologists experience TBA F0399BIn the eye of the public: politicised science, the microbiologists experience Marion Koopmans (Rotterdam, Netherlands) Co-organised with: European Centre for Disease Prevention and Control (ECDC) Sunday, 24 April 2022Scientific Programme ECCMID Open Forum 2022 Sunday 24 April 2022 12:15 – 13:15 WEST Arena 1 OPEN FORUM 2022 1-Hour Open Forum Chair:Jose Ramon Paño-Pardo, Zaragoza, Spain RIP my mentions: science by social media in the age of disinformation Angela Rasmussen, Saskatoon, Canada Is social media worth my time? Carlos del Rio, Atlanta, United States #IDTwitter: infectious diseases medicine in the age of social media Neil Stone, London, United Kingdom Bugs, drugs, and social media: Twitter as a tool foradvancingthefieldofinfectiousdiseases Timothy Gauthier, Miami, United States Is Twitter the new ID textbook?68FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 IC KN09613:30 - 14:30Hall A Keynote scientific interview Never let an outbreak go to waste: how COVID-19 has changed hospital epidemiology and infection prevention and control Interviewer Mary Horgan (Cork, Ireland) K040013:30 Alison Helen Holmes (Berlin, Germany) Alison Holmes is the Professor of Infectious Diseases and the Director of the NIHR Health Protection Research Unit in Healthcare Associated Infections and AMR and the Centre for Antimicrobial Optimisation (CAMO), at Imperial College London. She is also the current President of the International Society for Infectious Diseases. Prof. Holmes is an NIHR Senior Investigator and has a longstanding career in the NHS. She serves on WHO Expert groups related to antimicrobial use, AMR, infection prevention, sepsis, and COVID-19. She leads a large international, multidisciplinary infectious disease research programme, including collaborative programmes funded by NIHR, ESRC, UKRI and Wellcome Trust on the improved management and prevention of infections, particularly focusing on the optimising of antimicrobial use and addressing antimicrobial resistance through the integration of social sciences, the application of innovative approaches and technologies and the development of precision medicine. Co-organised with: European Committee on Infection Control (EUCIC) Steering Committee Fireplace Session24 April, 15:00 - 16:00 CM SY097 13:30 - 15:30 Hall B Symposium Impact of rapid diagnostics for community-acquired acute respiratory tract infections (CA-ARTI) on antibiotic stewardship ChairsMaurizio Sanguinetti (Rome, Italy) TBA S040113:30What is diagnostic stewardship and why should we care? Bhanu Sinha (Groningen, Netherlands) S040214:00Consensus about the use of rapid diagnostics for the management of CA-ARTI Eva Polverino (Barcelona, Spain) S040314:30Point-of-care testing and antibiotic prescribing for CA-ARTI in primary care during the COVID-19 pandemic Alike Van Der Velden (Utrecht, Netherlands) S040415:00Rapid diagnosis of CA-ARTI in the ambulatory care or in the emergency room: are there differences? Cristina Prat Aymerich (Utrecht, Netherlands) Co-organised with: VALUE-Dx, European Respiratory Society (ERS) PH SY098 13:30 - 15:30 Hall E Symposium Vaccinated or non-vaccinated: patients are not healthcare workers, and the flu is not COVID-19 ChairsWalter Zingg (Zurich, Switzerland) Nasia Safdar (Madison, United States) S040513:30How vaccines help healthcare workers to stay safe Martin Kiernan (Ormskirk, United Kingdom) S040614:00COVID-19 vaccine revisited: how to handle unvaccinated, poorly vaccinated or immunosuppressed patients Hilary Humphreys (Dublin, Ireland) S040714:30The triangle of personal protective equipment, vaccination and screening make our hospitals safe Nico Tom Mutters (Bonn, Germany) S040815:00Protecting the immunocompromised healthcare worker Gabriel Birgand (Nantes, France) Co-organised with: EUCIC Steering Committee ID SY099 13:30 - 14:30 Hall I Symposium The changing epidemiology of West Nile fever virus in Europe ChairsTamas Bakonyi (Solna, Sweden) TBA S040913:30Epidemiological trends West Nile virus in Western Europe Chantal B.E.M. Reusken (Bilthoven, Netherlands) S041014:00The causes and consequences of increasing West Nile virus activity in Europe Eleni Patsoula (Athens, Greece) Co-organised with: ESCMID Study Group for Public Health Microbiology (ESGPHM) Sunday, 24 April 2022Scientific Programme 69FINAL PROGRAMME – 32nd ECCMID Lisbon, Portugal 2022 ID EW100 13:30 - 15:30 Hall C Educational Workshop Subacute and chronic meningitis ChairsMatthijs Brouwer (Amsterdam, Netherlands) Emma Cecilia Wall (London, United Kingdom) W041113:30Infectious causes of chronic meningitis: diagnostic considerations and workup Bettina Pfausler (Innsbruck, Austria) W041214:00Non-infectious differential diagnosis in patients with subacute and chronic meningitis Uta Meyding-Lamadé (Frankfurt, Germany) W041314:30Post-Lyme disease syndrome: what is it and how to deal with it? Randi Eikeland (Kristiansand, Norway) Co-organised with: The Collaborative on Fatigue Following Infection (COFFI), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB) CM EW101 13:30 - 15:30 Hall F Educational Workshop Don’t get lost in translation: the use of preclinical PK/PD models in anti-infective drug development ChairsCornelia Landersdorfer (Parkville, Australia) Markus Zeitlinger (Vienna, Austria) W041413:30The role of in vitro models Alasdair P. MacGowan (Bristol, United Kingdom) W041514:00The role of in vivo models William Couet (Poitiers, France) W041615:00The role of in silico models Elisabet Nielsen (Uppsala, Sweden) Co-organised with: ESCMID PK/PD of Anti- Infectives Study Group (EPASG) PH EW102 13:30 - 15:30 Hall G Educational Workshop How to use intervention and implementation research to mitigate AMR ChairsBruno Gonzalez-Zorn (Madrid, Spain) Nandini Sreenivasan (Copenhagen, Denmark) W041713:30Intervention, operational and implementation research: key constructs Sabiha Essack (Durban, South Africa) W041814:00Developing an implementation research roadmap Raheelah Ahmad (London, United Kingdom), Alexandre Rabello Tenorio Da Costa (New York, United States) Co-organised with: International Centre for Antimicrobial Resistance Solutions (ICARS) OS103 13:30 - 15:30 Hall M 2-Hour Oral Session The Public Health response to COVID-19 ChairsDebby Bogaert (Edinburgh, United Kingdom) David Fisman (Toronto, Canada) O0419Genomic assessment of quarantine measures to prevent SARS-CoV-2 importation and transmission D. Aggarwal* (Cambridge, United Kingdom), A.J. Page, U. Schaefer, G.M. Savva, R. Myers, E. Volz, N. Ellaby, S. Platt, N. Groves, E. Gallaghar, N.M. Tumelty, T. Le-Viet, G.J. Hughes, C. Chen, C. Turner, S. Logan, A. Harrison, S.J. Peacock, M. Chand, E.M. Harrison O0420Lockdown impact on mixing patterns and behaviour relevant to the spread of infection in France during the COVID-19 pandemic R. Millot* (Poitiers, France), L. Opatowski, P. Beutels, N. Hens, B. Dervaux, G. Beraud O0421Impact of COVID-19 nationwide lockdowns on emergency hospitalisations due to chronic lower respiratory diseases: a national interrupted time series analysis for Ireland S. O’ Regan* (Dublin, Ireland), A. Mc Greal-Bellone, J. O’ Connell, P. Carey, A. Heeney, J. Harte, O. Donnelly, K. Bennett, E. De Barra O0422Fake news or credible source? Assessing the quality of online resources informing the public about COVID-19 in two countries C. Turnbull* (London, United Kingdom), J.K. Tan, L. Yamanouchi, J.Y. Tan, R. Som O0423Differences in diagnostic cycle threshold values of SARS-CoV-2 genes: a novel epidemiological tool to monitor variant prevalence A.E. Bordoy* (Barcelona, Spain), V. Saludes, D. Panisello, G. Clarà, A. París, C. Casañ, M. Guerrero-Murillo, B. Rodríguez-Ponga, M. Noguera-Julian, F. Català-Moll, P. Armengol, M. Casadellà, M. Parera, L. Sumoy, B. Clotet, M. Giménez, I. Blanco, E. Martró, P.J. Cardona O0424Estimation of the impact of hospital-onset SARS-CoV-2 infections on length of stay in English hospitals using causal inference J. Stimson* (London, United Kingdom), K. Pouwels, R. Hope, B. Cooper, A. Presanis, J. Robotham O0425Identifying targets for testing by machine learning Y. Asai* (Tokyo, Japan), S. Tsuzuki O0426Despite the level of uncontrolled spread of COVID-19 in Brazil, the country of soccer, can entire seasons of professional players be carried out safely? Yes, we did! C. Starling* (Belo Horizonte, Brazil), J. Pagura, A.D.C. Clovis, N. Roberto, W. Sergio, P. André, C. Sergio, P. Andreia, F. Sérgio, G. André, T. Edilson, C. Braulio Sunday, 24 April 2022Next >